Pediatrix Reports Strong 2025 Financial Turnaround, Initiates New $250M Share Repurchase Program
MD sits 74% above its 52-week low of $11.84.
Summary
Pediatrix reported a significant financial turnaround in 2025, moving from a net loss to a substantial net income, driven by strong operational improvements and strategic divestitures. The company also initiated a new $250 million share repurchase program.
Key Events · Earnings and Guidance · MD
-
Significant Financial Turnaround
The company reported a net income of $165.4 million in 2025, a substantial improvement from a net loss of $99.1 million in 2024, and diluted EPS of $1.94 compared to a loss of $1.19 per share in the prior year.
-
Strong Adjusted EBITDA Growth
Adjusted EBITDA increased to $275.6 million in 2025 from $224.0 million in 2024, reflecting enhanced profitability from core operations.
-
New Share Repurchase Program
Pediatrix repurchased $83.8 million of common stock in 2025 under a new $250 million authorization, demonstrating a commitment to returning capital to shareholders.
-
Improved Operational Efficiency & Liquidity
Cash flow from operating activities rose to $274.7 million in 2025 from $217.3 million in 2024, and Days Sales Outstanding (DSO) improved to 42.8 days from 47.6 days, indicating better cash collections.
Analysis · MD · Industrial Applications And Services
Pediatrix Medical Group, Inc. delivered a robust financial performance in 2025, marking a significant turnaround from prior year losses. The company reported net income of $165.4 million, a substantial improvement from a net loss of $99.1 million in 2024. This positive shift was driven by a 6.2% increase in same-unit net revenue, improved collection activities, and a favorable payor mix, demonstrating the benefits of its strategic portfolio optimization efforts, including the exit from non-core office-based and urgent care practices in 2024. Adjusted EBITDA also saw strong growth, increasing to $275.6 million from $224.0 million. Furthermore, the company enhanced shareholder value by repurchasing $83.8 million of common stock under a new $250 million program, with $166.2 million remaining available. The absence of goodwill impairment in 2025, following significant charges in the two prior years, indicates increased stability. While the company continues to navigate a complex regulatory environment, its improved liquidity, reduced debt, and strong operational performance position it favorably.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MD was trading at $20.65 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $11.84 to $24.99. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.